Finerenone showed kidney-protective effects and reduced cardiovascular risk in adults with non-diabetic chronic kidney disease in the Phase III FIND-CKD trial. The results were framed as part of the program’s evidence base for broadening finerenone’s potential use beyond diabetic populations. The report describes FIND-CKD as a pivotal Phase III study in adults with CKD without diabetes, highlighting slowed decline in kidney function alongside cardiovascular benefits. The trial was presented as the largest of its kind in this specific population. For nephrology drug development, the data strengthen the positioning of non-steroidal mineralocorticoid receptor antagonists as multi-system disease modifiers rather than kidney-only agents.